Price$9.08-0.42 (-4.42%)
01:30 PM07:45 PM
News · 26 weeks63+10%
2026-04-192026-10-11
Mix3190d
- Insider12(39%)
- Earnings6(19%)
- Other6(19%)
- SEC Filings5(16%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- PRCaspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and endogenous insulin production – – Investor webcast today, October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) plan to outline the development strategy for KO-7246, Caspian’s selective, oral menin inhibitor designed for diabetes and other chronic metabolic diseases, in a webcast later today. Management from both companies
- PRCaspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in DiabetesSAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) today announced they will host an investor webcast on Tuesday, October 13 at 4:30 p.m. ET. On the call, management from the companies will provide details regarding the formation of Caspian and will also review KO-7246 data featured in an oral presentation at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting. Virtual Investor EventCaspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast and replay will be available on www.kuraoncology.com under the Inves
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option ha
- ANALYSTAnalyst initiated coverage on Kura Oncology with a new price targetAnalyst initiated coverage of Kura Oncology with a rating of Overweight and set a new price target of $30.00
- INSIDERChief Legal Officer Bair Teresa Brophy sold $88,618 worth of shares (8,442 units at $10.50), decreasing direct ownership by 4% to 187,002 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Commercial Officer Powl Brian T. sold $345,036 worth of shares (32,450 units at $10.63) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 136,819 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSVP, Finance & Accounting Doyle Thomas James sold $48,361 worth of shares (4,607 units at $10.50), decreasing direct ownership by 3% to 142,428 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Medical Officer Leoni Mollie sold $440,237 worth of shares (41,250 units at $10.67) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 141,095 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Operating Officer Ford Kathleen sold $111,931 worth of shares (10,574 units at $10.59) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 142,986 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- PRCaspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes– KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models – – KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durability and combination benefit with semaglutide – – Findings highlight a potentially disease-modifying approach designed to restore the body’s own endogenous insulin-producing capacity – – Caspian is building a leadership position in menin-directed therapies for diabetes and other cardiometabolic diseases – – Management to host webcast and conference call on October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, Sept. 29, 2026
- INSIDERSEC Form 4 filed by Kura Oncology Inc.4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Fulk Jennifer4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fulk Jennifer3 - Kura Oncology, Inc. (0001422143) (Issuer)
- SECSEC Form 8-K filed by Kura Oncology Inc.8-K - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral presentation at European Association for the Study of Diabetes (EASD) Annual Meeting on September 29, 2026 – – Separately financed subsidiary provides dedicated capital and leadership to advance KO-724
- SECSEC Form 8-K filed by Kura Oncology Inc.8-K - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Appoints Jennifer Fulk as Chief Financial Officer– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leadership team and report to Troy Wilson, Ph.D., J.D., President, Chief Executive Officer and Chairman of the Board. "We are delighted to welcome Jennifer to Kura as we enter our next phase of develo
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option
- PRKura Oncology to Participate in Three Investor Conferences in SeptemberSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m. ET / 12:45 p.m. PT Cantor Global Healthcare ConferenceSeptember 9, 20269:10 a.m. ET / 6:10 a.m. PT Morgan Stanley Global Healthcare Conference September 16, 20267:45 a.m. ET / 4:45 a.m. PT Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three events. About Kura Oncology
- INSIDERChief Commercial Officer Powl Brian T. sold $51,663 worth of shares (4,345 units at $11.89) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 169,269 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERPresident and CEO Wilson Troy Edward bought $1,239,000 worth of shares (100,000 units at $12.39) (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Legal Officer Bair Teresa Brophy sold $397,681 worth of shares (31,487 units at $12.63) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 195,444 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERPresident and CEO Wilson Troy Edward bought $1,112,000 worth of shares (100,000 units at $11.12) (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- SECSEC Form 10-Q filed by Kura Oncology Inc.10-Q - Kura Oncology, Inc. (0001422143) (Filer)
- SECKura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kura Oncology, Inc. (0001422143) (Filer)
KURA FAQ
6 questionsWhat does Kura Oncology Inc. do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute...Where does KURA stock trade?
Kura Oncology Inc. (KURA) is listed on NASDAQ.What sector and industry is KURA in?
Kura Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KURA?
Kura Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $3000.00 price target on 2026-10-01. Recent price targets range from $1900.00 to $3100.00.What companies are similar to KURA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KURA side-by-side with any of them on Quantisnow.How can I track KURA on Quantisnow?
Quantisnow aggregates Kura Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KURA to receive live email and push alerts on every new disclosure.